Varlilumab (anti-CD27)

Varlilumab (CDX-1127) (anti-CD27) is an agonist anti-CD27 monoclonal antibody. Varlilumab (anti-CD27) can promote T cell expansion and activate the immune response. Varlilumab (anti-CD27) has anti-tumor activity and can be used in the research of hematological malignancies and solid tumors[1][2].

Product Specifications

CAS Number

[1393344-72-3]

Product Name Alternative

CDX-1127 (anti-CD27)

UNSPSC

12352203

Target

TNF Receptor; Transmembrane Glycoprotein

Type

Inhibitory Antibodies

Related Pathways

Apoptosis; Immunology/Inflammation

Applications

Cancer-programmed cell death

Field of Research

Cancer; Inflammation/Immunology

Assay Protocol

https://www.medchemexpress.com/varlilumab-anti-cd27.html

Purity

99.68

Solubility

10 mM in DMSO

Smiles

[Varlilumab(anti-CD27)]

Molecular Weight

(145.58 kDa)

References & Citations

[1]Stephen M Ansell, et al. Safety and activity of varlilumab, a novel and first-in-class agonist anti-CD27 antibody, for hematologic malignancies. Blood Adv. 2020 May 12;4 (9) :1917-1926.|[2]Wasiuk A, et al. Conditioning treatment with CD27 Ab enhances expansion and antitumor activity of adoptively transferred T cells in mice. Cancer Immunol Immunother. 2022 Jan;71 (1) :97-109.